Adults with a history of or at risk for a first atherosclerotic cardiovascular disease (ASCVD) event who received the oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor enlicitide ...

An investigational drug called lerodalcibep lowered low-density lipoprotein (LDL) cholesterol, or “bad” cholesterol, by 50% or more, a new study showed. The year-long clinical trial included people ...

Big news for those concerned about their heart health: Pharmaceutical company Merck has created a new pill called enlicitide, which promises to lower "bad" cholesterol as effectively as injectable ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with FDA approval for subcutaneous use. The LIBerate Program showed sustained ...

A new Merck pill called enlicitide slashes levels of harmful LDL cholesterol by up to 60%, similar to injectable PCSK9 drugs already on the market. File Photo by John Angelillo/UPI The drug, called ...

Later, researchers identified a protein called PCSK9, which reduces the number of these receptors and makes it harder for the ...

Merck & Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate ...

Phase 3 trial results show enlicitide, a once-daily oral PCSK9 inhibitor, cut LDL cholesterol by about 60% in high-risk ...

Sixteen received the injections intravenously and the others got simple injections that delivered the drug just underneath the skin. After the injections, bad cholesterol was measured frequently for ...